| Autor: |
Seiwerth, F., Bitar, L., Franolić, I. Lukić, Šajnić, A., Jakopović, M., Samaržija, M. |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Journal of Thoracic Oncology. 17:S426 |
| ISSN: |
1556-0864 |
| DOI: |
10.1016/j.jtho.2022.07.740 |
| Popis: |
Introduction Recent improvements in therapies for advanced non-small-cell lung cancer (NSCLC) have substantially increased patients’ quality of life and reduced mortality. Checkpoint inhibitors for patients without and new targeted therapies for patients with oncogenic driver mutations showed great clinical benefit. Treatment need for KRAS mutation has been unmet until sotorasib availability. Methods Patients with metastatic non-small-cell lung cancer were diagnosed with KRAS positive G12C mutation and treated with sotorasib, administered orally, with a dose of 960 mg once daily. The patients were enrolled in an early access program from May 2021 until December 2021 and were monitored for disease progression and side-effects until February 28th, 2022. Results We treated 4 patients with sotorasib since May 2021 until December 2021. KRAS G12C mutations were verified using next generation sequencing (FMI Roche). Two female and two male patients were involved, with a median age of 61 years (47-74). All of them were ex-somkers, with a median pack/year 20 (10-40). Three of them received sotorasib as a third line and one as fourth line therapy. All were previously treated with immune checkpoint inhibitors and platinum-based chemotherapy. Two patients had a Conclusions Sotorasib showed deffinitve clinical efficacy in NSCLC patients with KRAS G12C mutation. Liver enzyme elevation, as the most common side effect, seems to be menageable with drug dose reductions, while preserving its efficacy. Further data from larger patient cohorts as well as longer follow-up are needed to confirm these findings. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
